Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of BCG-PPD in Tuberculosis Patients
NCT04538911Phase 1Active, not recruiting
- Sponsor
- Zhifei Biological
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bacillus calmette-guérin purified protein derivative in Tuberculosis (TB) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Incidence of all adverse events and laboratory test results at 7 days and Size of skin response at 72 hours. Started Jul 2021; status: active, not recruiting.
02
Drugs
bacillus calmette-guérin purified protein derivative
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04538911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538911.